Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00112749 · ClinicalTrials.gov registry record · Phase 2
Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer
A Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT00112749: Clinical Trial Phase 2 study, sponsored by Jonsson Comprehensive Cancer Center.
NCT00112749 is a Phase 2 study that was terminated before completion, run by Jonsson Comprehensive Cancer Center. The registered enrollment target is 7 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00112749, a Phase 2 study, was terminated before completion, sponsored by Jonsson Comprehensive Cancer Center.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
RATIONALE: Infliximab may help improve energy levels in patients who have undergone treatment for breast cancer. PURPOSE: This phase II trial is studying how well infliximab works in treating cancer-related fatigue in postmenopausal women who have undergone treatment for stage 0, stage I, or stage II breast cancer.
Interventions
- BIOLOGICAL infliximab
- OTHER Clinical Assessment
- OTHER Self-report questionnaires
- OTHER Immune Assessment
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2005-02 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Why NCT00112749 stopped before completion
NCT00112749 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 4 interventions - of which infliximab is the first listed.
NCT00112749 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00112749 about?
NCT00112749 is a clinical study titled "Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer". RATIONALE: Infliximab may help improve energy levels in patients who have undergone treatment for breast cancer. PURPOSE: This phase II trial is studying how well infliximab works in treating cancer-related fatigue in postmenopausal women who have undergone treatment for stage 0, stage I, or stage ...
What is the current status of trial NCT00112749?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2005-02. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00112749?
The interventions under investigation include: infliximab (BIOLOGICAL), Clinical Assessment (OTHER), Self-report questionnaires (OTHER), Immune Assessment (OTHER).
Who is sponsoring clinical trial NCT00112749?
This trial is sponsored by Jonsson Comprehensive Cancer Center, which has 321 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00112749's enrollment target sits among peer trials
7 1996th of 2000 higher than 5 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia